Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Repurchased (2019 - 2025)

Historic Shares Repurchased for C4 Therapeutics (CCCC) over the last 5 years, with Q3 2025 value amounting to $24000.0.

  • C4 Therapeutics' Shares Repurchased fell 7176.47% to $24000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $334000.0, marking a year-over-year increase of 1023.1%. This contributed to the annual value of $194000.0 for FY2024, which is 7636.36% up from last year.
  • Latest data reveals that C4 Therapeutics reported Shares Repurchased of $24000.0 as of Q3 2025, which was down 7176.47% from $155000.0 recorded in Q1 2025.
  • In the past 5 years, C4 Therapeutics' Shares Repurchased ranged from a high of $155000.0 in Q1 2025 and a low of $16000.0 during Q3 2023
  • Moreover, its 3-year median value for Shares Repurchased was $89500.0 (2023), whereas its average is $80500.0.
  • Its Shares Repurchased has fluctuated over the past 5 years, first surged by 43125.0% in 2024, then plummeted by 7176.47% in 2025.
  • Over the past 3 years, C4 Therapeutics' Shares Repurchased (Quarter) stood at $16000.0 in 2023, then surged by 431.25% to $85000.0 in 2024, then crashed by 71.76% to $24000.0 in 2025.
  • Its last three reported values are $24000.0 in Q3 2025, $155000.0 for Q1 2025, and $85000.0 during Q3 2024.